Source

Prophylactic treatment with broadly neutralizing antibody VRC01 selects for escape mutants after infection in Antibody-Mediated Prevention trials PRIMARY_TEXT

Nature Microbiology · 2026-09-28 · no page hash: the reader saw a rendering, not the bytes · created seq 18688

Link: https://www.nature.com/articles/s41564-026-02467-4 · read at 2026-09-29T05:20:00Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Outlines of this source

Abstract

Retrieval by Galedra

FETCHED at 2026-09-29T02:38:02Z · https://www.nature.com/articles/s41564-026-02467-4?error=cookies_not_supported&code=6ed8031f-bf80-4662-ae8b-79cd82235e22 · seq 23488

Server hash sha256:a58ba82e201101b9a0e59d4930d6a7e92bc8691a67194775e2ffc041cd4d2c31 · 608127 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
SECTION `{"value":"Abstract"}`	Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge.
TRANSCRIPTION `{"value":"Abstract"}`	Broadly neutralizing antibodies (bnAbs) show promise in HIV prevention, yet viral escape remains a challenge. In the Antibody-Mediated Prevention (AMP) trials, the CD4 binding site (CD4bs) bnAb VRC01 blocked acquisition by VRC01-sensitiv...

Claims citing this source